Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-08-30 Annual Report
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Annual Financial Results Presentation 27 pages 1.8MB
Annual Report Classification · 95% confidence The document is a detailed presentation including operational highlights, financial results for the fiscal year ended June 30, 2022, clinical pipeline updates, and near-term milestones. It contains comprehensive financial data such as revenue, R&D spend, cash on hand, and loss before tax, as well as detailed descriptions of clinical trials and product development plans. The presence of full financial statements and substantive financial analysis for a full fiscal year indicates this is a comprehensive annual financial report. The document is not merely an announcement or a brief summary, nor is it a transcript, proxy, or regulatory filing. Therefore, it fits the definition of an Annual Report (10-K).
2022-08-30 English
MSB Annual Financial Results and Operational Highlights 8 pages 338.3KB
Annual Report Classification · 95% confidence The document is a detailed report from Mesoblast Limited presenting financial results and operational highlights for the fiscal year ended June 30, 2022. It includes comprehensive financial data such as cash on hand, revenue, expenses, net loss, and detailed operational updates on product development and regulatory milestones. The presence of full financial figures, discussion of business trends, and outlook statements indicates this is a full annual financial report rather than a brief earnings release or announcement. The document also references the fiscal year explicitly and provides a conference call for further discussion, which is typical for annual reports. Therefore, this document fits the definition of an Annual Report (10-K).
2022-08-30 English
Mesoblast 2022 Full Year Financial Results Webcast 1
Investor Presentation Classification · 90% confidence The document is a corporate update announcing a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2022. It provides details about the webcast timing and access, company background, and contact information. There are no actual financial statements or detailed financial data included in the text. The document serves as an announcement for an upcoming webcast rather than the financial report itself. Given the short length (2903 characters) and the nature of the content, this fits the profile of an Investor Presentation (IP) announcement or a webcast notice. However, since it is specifically about a webcast discussing financial results and operational highlights, it aligns best with the Investor Presentation (IP) category, which covers detailed presentations for investors focusing on financials, strategy, and market position. Therefore, the classification is IP with high confidence.
2022-08-29 English
6-K
Regulatory Filings
2022-08-20 English
Final Director's Interest Notice 2 pages 229.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including options held, and the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director's securities interests, with no financial statements or other report content. Therefore, it fits the Director's Dealing (DIRS) category.
2022-08-17 English
Initial Director's Interest Notice 2 pages 314.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director's Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, specifically the number and class of shares held by the director. This is a report of personal share transactions or holdings by a company director. The document length is short and focused solely on director's share interests, matching the definition of Director's Dealing filings.
2022-08-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.